---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-023789"
form_type: "8-K"
ticker: "RFL"
cik: "0001713863"
company_name: "Rafael Holdings, Inc."
filed_at: "2025-03-14T23:59:59+00:00"
generated_at: "2026-05-24T18:40:13.267061+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rafael Holdings Q2 net loss $4.6M vs prior year net income; merger with Cyclo pending

## Summary
- Net loss of $4.6M ($0.19/sh) for Q2 ended Jan 31, 2025 vs net income of $6.0M ($0.25/sh) a year ago.
- Cash and equivalents at $48.3M as of January 31, 2025.
- Merger with Cyclo Therapeutics (CYTH) expected to close in Q3 fiscal 2025 pending shareholder approvals.
- Topline data from interim analysis (48 weeks) of Phase 3 Trappsol Cyclo for NPC1 expected mid-2025.
- R&D expenses rose to $0.9M from $0.6M due to consolidation of Cornerstone and Day Three.

## SEC filing metadata
- accession: 0001213900-25-023789
- form_type: 8-K
- ticker: RFL
- cik: 0001713863
- company_name: Rafael Holdings, Inc.
- filed_at: 2025-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1713863/000121390025023789/0001213900-25-023789-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1713863/000121390025023789/ea0234181-8k_rafael.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-023789
- JSON: https://secwatch.observer/filing/0001213900-25-023789.json
- Plain text: https://secwatch.observer/filing/0001213900-25-023789.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.